CoChat
Sign Up
Cited by 22Lung Cancer Diagnosis and TreatmentInflammatory Biomarkers in Disease PrognosisMedical Imaging Techniques and Applications

The relationship between 18F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer

Open access
Dolan, Ross D., Maclay, John D., Abbass, Tanvir, Colville, David, Buali, Fatema, MacLeod, Nicholas, McSorley, Stephen T., Horgan, Paul G. +1 more·2020·Scientific Reports
DOI 10.1038/s41598-020-77269-7PMC PMC7705735
Open this paper in CoChat — free accountOpen PDF

Abstract

The aim of this study was to examine the relationship between PET-CT derived tumour glucose uptake as measured by maximum standard glucose uptake (SUVmax) and total lesion glycolysis (TLG), nutritional risk as measured by the malnutrition universal screening tool (MUST), CT derived body composition as measured by skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD), the systemic inflammatory response as measured by the modified Glasgow prognostic score (mGPS) and the neutrophil to lymphocyte ratio (NLR) and survival in patients with lung cancer, treated with radiotherapy. In a retrospective cohort study, 119 patients were included in final analyses. The majority of patients were over 65 (86%), female (52%), had a performance status (ECOG-PS) of 0 or 1 (57%), were at nutritional risk (57%), were overweight (53%), had visceral obesity (62%), had a normal SMI (51%), had a low SMD (62%) and were systemically inflammed (mGPS 1/2, 51%). An elevated TLG was associated with sex (p < 0.05), TNM stage (p < 0.001), MUST (p < 0.01) and mGPS (p < 0.01). An elevated mGPS was associated with age (p < 0.05), NLR (p < 0.01), MUST (p < 0.01), and TLG (p < 0.01). On univariate survival analysis, TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p ≤ 0.001), Low SMD (p < 0.05), SUVmax (p ≤ 0.001) and TLG (p < 0.001) were associated with overall survival. On multivariate survival analysis MUST (HR: 1.49 95%CI 1.12–01.98 p < 0.01) and TLG (HR: 2.02 95%CI 1.34–3.04 p = 0.001) remained independently associated with survival. In conclusion, elevated tumour metabolic activity was associated with more advanced stage, greater nutritional risk, the systemic inflammatory response and poorer survival but not body composition analysis in patients with lung cancer. These results suggest that detrimental body composition is not directly determined by tumour metabolic activity but rather an ongoing systemic inflammatory response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-77269-7

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated tumor metabolic activity determined by TLG was associated with greater nutritional risk (GPS) and systemic inflammatory response (NLR) in patients with NSCLC.

    “Dolanetal reported that elevated tumor metabolic activity determined by TLG was associated with greater nutritional risk (GPS) and systemic inflammatory response (NLR) in patients with NSCLC(14).”

    From Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. (2024) · cites this paper as [14]

    The Results report that TLG was significantly associated with mGPS, and the Discussion links TLG and mGPS with nutritional risk in patients with lung cancer. The Results also indicate that patients with small-cell lung cancer were excluded. However, the paper identifies mGPS as a measure of systemic inflammation and MUST as the nutritional-risk tool; the passages do not establish the claimed TLG–NLR association. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • A close relationship exists between 18F-FDG uptake and inflammatory indices in patients with NSCLC.

    “A recent study demonstrated a close relationship between 18F‑FDG uptake and inflammatory indices in patients with NSCLC (14).”

    From Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. (2024) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 47 · Cited by 22

Research works printed but not linked: 45

  1. [2]Roxburgh CS McMillan DC Role of systemic inflammatory response in predicting survival in patients with primary operable cancer Future Oncol. 2010 6 149 163 10.2217/fon.09.136 20021215 · DOI
  2. [3]Proctor MJ A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study Eur. J. Cancer 2011 47 2633 2641 10.1016/j.ejca.2011.03.028 21724383 · DOI
  3. [4]Torre LA Global cancer statistics, 2012 CA Cancer J. Clin. 2015 65 87 108 10.3322/caac.21262 25651787 · DOI
  4. [6]Daly LE Prado CM Ryan AM A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes Proc. Nutr. Soc. 2018 77 135 151 10.1017/s0029665118000046 29745361 · DOI
  5. [7]Martin L Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index J. Clin. Oncol. 2013 31 1539 1547 10.1200/jco.2012.45.2722 23530101 · DOI
  6. [8]Malietzis G Influence of body composition profile on outcomes following colorectal cancer surgery Br. J. Surg. 2016 103 572 580 10.1002/bjs.10075 26994716 · DOI
  7. [9]Feliciano EMC Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study JAMA Oncol. 2017 3 e172319 10.1001/jamaoncol.2017.2319 28796857 PMC5824285 · DOI
  8. [10]Prado CM Cushen SJ Orsso CE Ryan AM Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact Proc. Nutr. Soc. 2016 75 188 198 10.1017/s0029665115004279 26743210 · DOI
  9. [11]Cederholm T ESPEN guidelines on definitions and terminology of clinical nutrition Clin. Nutr. 2017 36 49 64 10.1016/j.clnu.2016.09.004 27642056 · DOI · Paper page
  10. [12]Miele E Positron Emission Tomography (PET) radiotracers in oncology–utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC) J. Exp. Clin. Cancer Res. 2008 27 52 10.1186/1756-9966-27-52 18928537 PMC2579910 · DOI
  11. [13]Griffeth LK Use of PET/CT scanning in cancer patients: technical and practical considerations Proc. Bayl. Univ. Med. Cent. 2005 18 321 330 10.1080/08998280.2005.11928089 16252023 PMC1255942 · DOI
  12. [14]Dolan RD The relationship between tumour glucose metabolism and host systemic inflammatory responses in patients with cancer: a systematic review J. Nucl. Med. 2018 10.2967/jnumed.118.216697 30166353 · DOI
  13. [15]Dolan RD Lim J McSorley ST Horgan PG McMillan DC The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis Sci. Rep. 2017 7 16717 10.1038/s41598-017-16955-5 29196718 PMC5711862 · DOI
  14. [16]Dolan RD McSorley ST Horgan PG Laird B McMillan DC The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis Crit. Rev. Oncol. Hematol. 2017 116 134 146 10.1016/j.critrevonc.2017.06.002 28693795 · DOI
  15. [17]McMillan DC Systemic inflammation, nutritional status and survival in patients with cancer Curr. Opin. Clin. Nutr. Metab. Care 2009 12 223 226 10.1097/MCO.0b013e32832a7902 19318937 · DOI
  16. [18]Douglas E McMillan DC Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score Cancer Treat. Rev. 2014 40 685 691 10.1016/j.ctrv.2013.11.007 24321611 · DOI
  17. [19]Arends J ESPEN expert group recommendations for action against cancer-related malnutrition Clin. Nutr. 2017 36 1187 1196 10.1016/j.clnu.2017.06.017 28689670 · DOI · Paper page
  18. [20]Richards CH The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer PLoS ONE 2012 7 e41883 10.1371/journal.pone.0041883 22870258 PMC3411715 · DOI
  19. [21]Malietzis G Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer Ann. Surg. 2016 263 320 325 10.1097/sla.0000000000001113 25643288 · DOI
  20. [22]Kim EY The relationship between sarcopenia and systemic inflammatory response for cancer cachexia in small cell lung cancer PLoS ONE 2016 11 e0161125 10.1371/journal.pone.0161125 27537502 PMC4990336 · DOI
  21. [23]Rollins KE The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma Clin. Nutr. 2016 35 1103 1109 10.1016/j.clnu.2015.08.005 26411749 · DOI
  22. [24]Black D Prognostic value of computed tomography: measured parameters of body composition in primary operable gastrointestinal cancers Ann. Surg. Oncol. 2017 24 2241 2251 10.1245/s10434-017-5829-z 28324283 PMC5491683 · DOI
  23. [25]McSorley ST Black DH Horgan PG McMillan DC The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer Clin. Nutr. 2017 10.1016/j.clnu.2017.05.017 28566220 · DOI
  24. [26]Dolan RD The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer J. Cachexia Sarcopenia Muscle 2019 10 111 122 10.1002/jcsm.12357 30460764 PMC6438413 · DOI
  25. [27]Inoue K Goto R Okada K Kinomura S Fukuda H A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity Ann. Nucl. Med. 2009 23 643 649 10.1007/s12149-009-0286-9 19629627 · DOI
  26. [28]Mirsadraee S Oswal D Alizadeh Y Caulo A van Beek E The 7th lung cancer TNM classification and staging system: review of the changes and implications World J. Radiol. 2012 4 128 134 10.4329/wjr.v4.i4.128 22590666 PMC3351680 · DOI
  27. [29]McSorley ST The relationship between 18F FDG-PETCT derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer Colorectal Dis. 2017 10.1111/codi.13973 29178362 · DOI
  28. [30]Watt DG Martin JC Park JH Horgan PG McMillan DC Neutrophil count is the most important prognostic component of the differential white cell count in patients undergoing elective surgery for colorectal cancer Am. J. Surg. 2015 210 24 30 10.1016/j.amjsurg.2014.12.031 25842358 · DOI
  29. [31]McMillan DC Cancer and systemic inflammation: stage the tumour and stage the host Br. J. Cancer 2013 109 529 10.1038/bjc.2013.418 23921279 PMC3738113 · DOI
  30. [32]Dolan RD The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores Br. J. Cancer 2018 119 40 51 10.1038/s41416-018-0095-9 29789606 PMC6035216 · DOI
  31. [33]McSorley ST Black DH Horgan PG McMillan DC The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer Clin. Nutr. 2018 37 1279 1285 10.1016/j.clnu.2017.05.017 28566220 · DOI
  32. [34]Doyle SL Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research Nutr. Res. 2013 33 171 179 10.1016/j.nutres.2012.12.007 23507222 · DOI
  33. [36]Boellaard R FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 Eur. J. Nucl. Med. Mol. Imaging 2015 42 328 354 10.1007/s00259-014-2961-x 25452219 PMC4315529 · DOI · Paper page
  34. [37]Dolan RD The relationship between longitudinal changes in CT derived body composition, clinicopathological characteristics and the systemic inflammatory response in patients undergoing surgery for colorectal cancer J. Clin. Oncol. 2018 10 111 122 PMC6438413 30460764
  35. [38]Abbass T Dolan RD Laird BJ McMillan DC The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients Cancers 2019 10.3390/cancers11091304 31487957 PMC6770798 · DOI
  36. [39]Guthrie GJ Roxburgh CS Richards CH Horgan PG McMillan DC Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer Br. J. Cancer 2013 109 131 137 10.1038/bjc.2013.291 23756867 PMC3708575 · DOI
  37. [40]O'Callaghan DS O'Donnell D O'Connell F O'Byrne KJ The role of inflammation in the pathogenesis of non-small cell lung cancer J. Thorac. Oncol. 2010 5 2024 2036 10.1097/JTO.0b013e3181f387e4 21155185 · DOI
  38. [41]McAllister SS Weinberg RA The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis Nat. Cell Biol. 2014 16 717 727 10.1038/ncb3015 25082194 PMC6220424 · DOI
  39. [42]Diakos CI Charles KA McMillan DC Clarke SJ Cancer-related inflammation and treatment effectiveness Lancet Oncol. 2014 15 e493 503 10.1016/s1470-2045(14)70263-3 25281468 · DOI · Paper page
  40. [43]Laird BJ Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response J. Clin. Oncol. 2016 34 2769 2775 10.1200/jco.2015.65.7742 27354484 PMC5019748 · DOI · Paper page
  41. [44]Park JH Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer Br. J. Cancer 2017 116 1444 1450 10.1038/bjc.2017.108 28427085 PMC5520088 · DOI
  42. [45]Galon J Towards the introduction of the 'Immunoscore' in the classification of malignant tumours J. Pathol. 2014 232 199 209 10.1002/path.4287 24122236 PMC4255306 · DOI
  43. [46]Mesker WE The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage Cell. Oncol. 2007 29 387 398 17726261 PMC4617992
  44. [47]Park JH McMillan DC Outcome in colorectal cancer-tumour, stroma and so much more Ann. Oncol. 2018 29 534 535 10.1093/annonc/mdy007 29324981 · DOI
  45. [48]Maguire J SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status Eur. J. Cancer 2014 50 2939 2949 10.1016/j.ejca.2014.07.009 25304298 · DOI

Authors
Dolan, R. D., Maclay, J. D., Abbass, T., Colville, D., Buali, F., MacLeod, N., McSorley, S. T., Horgan, P. G., & McMillan, D. C.
Affiliations
  • Glasgow Royal Infirmary (GB)
  • Gartnavel General Hospital (GB)
  • Beatson West of Scotland Cancer Centre (GB)
Corresponding author
Dolan, Ross D.
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2020-11-30
Volume
10
Issue
1
Pages
20819-20819
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-020-77269-7
PMC
PMC7705735
OpenAlex
W3107230289
Cited by
22
References
47
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 1
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Funders
  • University of Glasgow (Clinical Research Fellow Fund, Clinical Nutrition Research Fund)
  • NHS Greater Glasgow and Clyde (Endowment Fund)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
lung cancer, 18F-FDG PET/CT, tumor glucose metabolism, total lesion glycolysis, SUVmax, nutritional risk, malnutrition, skeletal muscle index, skeletal muscle radiodensity, systemic inflammation, modified Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio, overall survival, radiotherapy, body composition, prognostic factors, TNM stage
MeSH terms
Positron Emission Tomography Computed Tomography, Aged, Body Composition, Female, Glucose, Glycolysis, Humans, Inflammation, Lung Neoplasms, Male, Middle Aged, Nutritional Status, Prognosis, Risk Factors, Survival Analysis, Radiopharmaceuticals, Fluorodeoxyglucose F18, Malnutrition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review